Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue: +1.33%
EPS: +418.2%
Free cash flow: −6.83%
Total debt: −42.2%

Quarter to June 2026, against a year earlier

72.79 0.13 +0.18%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.2×
Fwd P/E: 54.2×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Techne Corp (TECH) Debt to equity

Alert me on Debt to equity

Bio-Techne Corp's debt to equity at the end of the quarter to 30 June 2026 was 0.1×. Over the past ten years it has ranged from 0.1× (fiscal 2015) to 0.4× (fiscal 2019); the current reading is higher than 17% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TECH/debt-to-equity" width="100%" height="360" style="border:0" loading="lazy" title="Bio-Techne Corp debt to equity, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TECH/metrics/debt-to-equity">Bio-Techne Corp (TECH) debt to equity — stockrow.com</a></p>

Period	Debt to equity	Change
FY2026	0.1×	(47.37%)
FY2025	0.2×	16.93%
FY2024	0.2×	(13.37%)
FY2023	0.2×	18.35%
FY2022	0.2×	(30.76%)
FY2021	0.2×	(15.91%)
FY2020	0.3×	(40.40%)
FY2019	0.4×	37.94%
FY2018	0.3×	(13.20%)
FY2017	0.4×	233.33%

Period	Debt to equity	Change
Jun 2026	0.1×	(1.04%)
Mar 2026	0.1×	(25.83%)
Dec 2025	0.1×	(15.27%)
Sep 2025	0.2×	(15.36%)
42 more quarters	Free account

Against its own ten years

Low 0.1× High 0.4×

Ten-year median 0.2×

Current reading's percentile 17

Company	Debt to equity
IBRX ImmunityBio, Inc. compare	−0.7×
CAI Caris Life Sciences,�Inc. compare	0.0×
SMMT Summit Therapeutics PLC compare	0.0×
PCVX Vaxcyte, Inc. compare	0.0×
KYMR Kymera Therapeutics, Inc. compare	0.0×
TWST Twist Bioscience Corporation compare	0.0×
TECH Bio-Techne Corp	0.1×
BMRN BioMarin Pharmaceutical Inc. compare	0.7×
TGTX TG Therapeutics, Inc. compare	1.2×
Biotechnology industry median	0.0×
Healthcare sector median	0.0×
Market median	0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

Bio-Techne Corp (TECH) Debt to equity

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on TECH

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on TECH

Stockrow Weekly